[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Romagné et al., 2011 - Google Patents

Natural killer cell-based therapies

Romagné et al., 2011

View HTML
Document ID
1004231435826429459
Author
Romagné F
Vivier E
Publication year
Publication venue
F1000 medicine reports

External Links

Snippet

Allotransplantation of natural killer (NK) cells has been shown to be a key factor in the control and cure of at least some hematologic diseases, such as acute myeloid leukemia or pediatric acute lymphocytic leukemia. These results support the idea that stimulation of NK …
Continue reading at www.ncbi.nlm.nih.gov (HTML) (other versions)

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48Reproductive organs
    • A61K35/54Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Micro-organisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof

Similar Documents

Publication Publication Date Title
Wolf et al. Novel approaches to exploiting invariant NKT cells in cancer immunotherapy
Romagné et al. Natural killer cell-based therapies
Giganti et al. Treg cell therapy: How cell heterogeneity can make the difference
Bachanova et al. NK cells in therapy of cancer
Szmania et al. Ex vivo–expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients
Wiebking et al. Genome editing of donor-derived T cells to generate allogeneic chimeric antigen receptor-modified T cells: optimizing αβ T-cell-depleted haploidentical hematopoietic stem cell transplantation
Davies et al. Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease
Spel et al. Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma
Heinrichs et al. Regulatory T-cell therapy for graft-versus-host disease
Locatelli et al. At the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies
Scheper et al. Cancer immunotherapy using γδT cells: dealing with diversity
Kannan et al. Natural killer cells in malignant hematology: A primer for the non-immunologist
CN106661129A (en) Chimeric antigen receptor specific for SSEA4 antigen
Torelli et al. A good manufacturing practice method to ex vivo expand natural killer cells for clinical use
Norell et al. At the Bench: Preclinical rationale for exploiting NK cells and γδ T lymphocytes for the treatment of high-risk leukemias
Besser et al. Development of allogeneic NK cell adoptive transfer therapy in metastatic melanoma patients: in vitro preclinical optimization studies
Moretta et al. Human NK receptors: from the molecules to the therapy of high risk leukemias
Ghio et al. Down regulation of human natural killer cell–mediated cytolysis induced by blood transfusion: role of transforming growth factor‐β1, soluble Fas ligand, and soluble Class I human leukocyte antigen
Biernacki et al. T cell optimization for graft-versus-leukemia responses
Hont et al. The generation and application of antigen-specific T cell therapies for cancer and viral-associated disease
WO2016185476A1 (en) Methods of obtaining mononuclear blood cells and uses thereof
Pierini et al. NK cell and CD4+ FoxP3+ regulatory T cell based therapies for hematopoietic stem cell engraftment
Schmid et al. Human invariant natural killer T cells promote tolerance by preferential apoptosis induction of conventional dendritic cells
Zhang et al. Imm TAC/Anti‐PD‐1 antibody combination to enhance killing of cancer cells by reversing regulatory T‐cell‐mediated immunosuppression
Duan et al. Targeting NK cells for HIV-1 treatment and reservoir clearance